Although Eisai Co. Ltd./Arena Pharmaceuticals Inc.have decided to price their obesity drug Belviq (lorcaserin) at a premium to rival drug Qsymia (phentermine/topiramate), consumer incentive programs will help to drive use of the product once it is launched, Arena CEO Jack Leif indicated during the company’s year-end sales and earnings call March 4.
Price is particularly important in the area of obesity, where drugs are not widely reimbursed and most patients pay out of pocket. But Leif said the amount patients will actually...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?